Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Century TherapeuticsIPSC +0.95%46 Cash-to-Debt is 3.10 as of Jun. 2026, which is 16% below its 10-year median of 3.68. GuruFocus rates IPSC with a GF Score™ of 46/100 and a GF Value™ of $40.02 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,397 Biotechnology companies, Century Therapeutics ranks worse than 61.13% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Century Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was 3.10.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Century Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Century Therapeutics's Cash-to-Debt or its related term are showing as below:
IPSC'
s Cash-to-Debt Range Over the Past 10 Years
Min: 2.69 Med: 3.68 Max: No Debt
Current: 3.1
During the past 7 years, Century Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 2.69. And the median was 3.68.
IPSC's Cash-to-Debt is ranked worse than 61.13% of 1397
companies
in the Biotechnology industry
Industry Median: 6.64
vs IPSC: 3.10
Century Therapeutics (NAS:IPSC) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Century Therapeutics Cash-to-Debt Related Terms
Century Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Century Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Century Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Century Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Century Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Century Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Century Therapeutics (IPSC) has a Cash-to-Debt of 3.10 as of Jun. 2026. This is 16% below median its historical median of 3.68. Over the past decade, Century Therapeutics' Cash-to-Debt has ranged from 2.69 to 10,000.00. According to the industry distribution chart, Century Therapeutics ranks #854 out of 1397 companies in the Biotechnology industry, placing it in the top 61.1%.
Is Century Therapeutics' Cash-to-Debt too high?
Century Therapeutics' current Cash-to-Debt of 3.10 is 16% below median its 10-year median of 3.68. Over the past 10 years, this metric has ranged from a low of 2.69 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.64. Century Therapeutics' value of 3.10 is 53.3% below this industry median. Based on the distribution chart, Century Therapeutics ranks #854 out of 1397 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Century Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Century Therapeutics' Cash-to-Debt compare to UPB and ZNTL?
According to the Biotechnology industry distribution chart, Century Therapeutics ranks #854 out of 1397 companies for Cash-to-Debt. This places Century Therapeutics in the lower half of its industry. The industry median Cash-to-Debt is 6.64. Century Therapeutics' value of 3.10 is 53.3% below this benchmark. Historically, Century Therapeutics' own Cash-to-Debt has ranged from 2.69 to 10,000.00 over the past decade. While the company's 10-year median is 3.68 vs. the industry median of 6.64, Century Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.64, based on 1,397 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Century Therapeutics's current Cash-to-Debt of 3.10 is 53.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Century Therapeutics's current Cash-to-Debt is 3.10, which is 16% below median its own 10-year median of 3.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Century Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Century Therapeutics (IPSC) is currently considered Possible Value Trap. The stock's GF Value™ is $40.02, compared to a current price of $2.13 — trading 94.7% below its estimated fair value. The current Cash-to-Debt is 3.10, which is 16% below median its 10-year median of 3.68 and 53.3% below the Biotechnology industry median of 6.64. Century Therapeutics' overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Century Therapeutics (IPSC), the current Cash-to-Debt is 3.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Century Therapeutics (IPSC) Overvalued in 2026?
Based on GuruFocus' analysis, Century Therapeutics stock appears to be undervalued.
The current stock price of $2.13 is trading 94.7% below its estimated GF Value™ of $40.02.
GuruFocus considers Century Therapeutics to be Possible Value Trap.
Key valuation signals for IPSC:
Cash-to-Debt: 3.10 (16% below median its 10-year median of 3.68)
GF Value™: $40.02 vs. price of $2.13 (94.7% below fair value)
Industry Position: 53.3% below the Biotechnology median (#854 of 1397)
No single metric tells the full story. See the IPSC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
46GF Score
Get the complete analysis for IPSC
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPSC has been successfully added to your 
